About: Associations of Clinical Characteristics and Treatment Regimens with Viral RNA Shedding Duration in Patients with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Associations of Clinical Characteristics and Treatment Regimens with Viral RNA Shedding Duration in Patients with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Associations of Clinical Characteristics and Treatment Regimens with Viral RNA Shedding Duration in Patients with COVID-19
Creator	Wang, Jian Hong, Wenxin Deng, Ying Zhang, Yuying He, Xi Chan, Juliana Zeng, Chen, Xudan Baoyi, Zhu Chen, Jingfeng Qiu, Shuang Zheng, Haipeng Deng, Qiu Jc, Chan Zeng, Jianwen Zhu, Baoyi
Source	Elsevier; Medline; PMC
abstract	Abstract Objective The novel coronavirus disease 2019 (COVID-19) has become a global pandemic, but the factors influencing viral RNA shedding remain unclear to inform optimal control strategies. Methods The clinical course and viral RNA shedding pattern of 267 consecutive symptomatic COVID-19 patients admitted to the hospital from January 20, 2020 to March 15, 2020 were retrospectively evaluated. Results The median viral RNA shedding duration was 12 days (interquartile range, 8–16 d) after the onset of illness. Of the 267 patients included in this study, 65.2% had viral RNA cleared within 14 days, 88.8% within 21 days, and 94.4% within 28 days. Older age (hazard ratio [HR], 0.99; 95% confidence interval [CI]: 0.98–1.00; P = 0.04), time lag from illness onset to hospital admission (HR, 0.91; 95% CI: 0.88–0.94; P < 0.001), diarrhea (HR, 0.59; 95% CI: 0.36–0.96; P = 0.036), corticosteroid treatment (HR, 0.60; 95% CI: 0.39–0.94; P = 0.024), and lopinavir/ritonavir use (HR, 0.70; 95% CI: 0.52–0.94; P = 0.014) were significantly independently associated with prolonged viral RNA shedding. Conclusions Early detection and timely hospital admission may be warranted for symptomatic COVID-19 patients, especially for older patients and patients with diarrhea. Corticosteroid treatment is associated with prolonged viral RNA shedding and should be used with caution. Lopinavir/ritonavir use may be associated with prolonged viral RNA shedding in non-severe patients; further randomized controlled trials are needed to confirm this finding.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.1016/j.ijid.2020.06.091
bibo:pmid	32619760
has license	els-covid
sha1sum (hex)	4bccb4fc03dd51fc19bd00c2abb3804cebf36790
schema:url	https://doi.org/10.1016/j.ijid.2020.06.091
resource representing a document's title	Associations of Clinical Characteristics and Treatment Regimens with Viral RNA Shedding Duration in Patients with COVID-19
has PubMed Central identifier	PMC7326382
has PubMed identifier	32619760
schema:publication	Int J Infect Dis
resource representing a document's body	covid:4bccb4fc03dd51fc19bd00c2abb3804cebf36790#body_text
is schema:about of	named entity 'viral' named entity 'Duration' named entity 'EMAIL' named entity 'International Journal of Infectious Diseases' named entity 'Treatment Regimens' named entity 'COVID-19' named entity 'coronavirus' named entity 'lopinavir/ritonavir' named entity 'RNA' named entity 'infection' named entity 'viral shedding' named entity 'Guangzhou' named entity 'cardiovascular diseases' named entity 'oxygen saturation' named entity 'demographic' named entity 'normal body temperature' named entity 'COVID-19' named entity 'older age' named entity 'China' named entity 'viral shedding' named entity 'viral RNA' named entity 'respiratory tract' named entity 'viral RNA' named entity 'hypertension' named entity 'confounders' named entity 'diarrhea' named entity 'antibiotics' named entity 'computed tomography' named entity 'viral RNA' named entity 'fraction of inspired oxygen' named entity 'Middle East Respiratory Syndrome' named entity 'Decreased lymphocyte count' named entity 'procalcitonin' named entity 'viral shedding' named entity 'protease inhibitors' named entity 'critical illness' named entity 'regression analysis' named entity 'critical illness' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'global public health' named entity 'viral RNA' named entity 'viral RNA' named entity 'comorbid disease' named entity 'corticosteroid' named entity 'older age' named entity 'China' named entity 'oxygen therapy' named entity 'COVID' named entity 'human immunodeficiency virus' named entity 'diarrhea' named entity 'controlled trial' named entity 'viral RNA' named entity 'COVID' named entity 'mmHg' named entity 'partial pressure of arterial oxygen' named entity 'Older age' named entity 'pulse oximeter' named entity 'risk factors' named entity 'demographic' named entity 'corticosteroid' named entity 'incubation period' named entity 'viral RNA' named entity 'reverse transcription-polymerase chain reaction' named entity 'antibiotics' named entity 'Critical illness' named entity 'Statistical analysis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software